Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

WuXi PharmaTech Announces Outstanding Q3 Numbers

publication date: Nov 10, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
WuXi PharmaTech reported impressive Q3 results, showing that the Shanghai-based CRO is continuing to prosper on all fronts. The company said its revenues were 20% higher than the year-earlier quarter at $83.8 million, and non-GAAP net income rose 27% to $22.4 million. GAAP numbers were even higher as WuXi booked a $30 million breakup fee from Charles River Labs, which decided in Q2 not to proceed with its acquisition of WuXi PharmaTech. More details....

Stock Symbols: (NYSE: WX) (NYSE: CRL)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners